JP2024513227A - Ｎｅｋ７阻害剤 - Google Patents

Ｎｅｋ７阻害剤 Download PDF

Info

Publication number
JP2024513227A
JP2024513227A JP2023561240A JP2023561240A JP2024513227A JP 2024513227 A JP2024513227 A JP 2024513227A JP 2023561240 A JP2023561240 A JP 2023561240A JP 2023561240 A JP2023561240 A JP 2023561240A JP 2024513227 A JP2024513227 A JP 2024513227A
Authority
JP
Japan
Prior art keywords
compound according
mmol
pyrimidin
amino
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513227A5 (https=
Inventor
ジェイムズ ベアス，デイビッド
サイ ケオン，ザ サード カウウェ，ジョン
アンリ アベル モラール，アレクシ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Halia Therapeutics Inc
Original Assignee
Halia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halia Therapeutics Inc filed Critical Halia Therapeutics Inc
Publication of JP2024513227A publication Critical patent/JP2024513227A/ja
Publication of JP2024513227A5 publication Critical patent/JP2024513227A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023561240A 2021-04-05 2022-04-05 Ｎｅｋ７阻害剤 Pending JP2024513227A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163170708P 2021-04-05 2021-04-05
US63/170,708 2021-04-05
US202163185282P 2021-05-06 2021-05-06
US63/185,282 2021-05-06
PCT/US2022/023443 WO2022216680A1 (en) 2021-04-05 2022-04-05 Nek7 inhibitors

Publications (2)

Publication Number Publication Date
JP2024513227A true JP2024513227A (ja) 2024-03-22
JP2024513227A5 JP2024513227A5 (https=) 2025-04-10

Family

ID=81448482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561240A Pending JP2024513227A (ja) 2021-04-05 2022-04-05 Ｎｅｋ７阻害剤

Country Status (12)

Country Link
US (1) US20240317758A1 (https=)
EP (1) EP4320127A1 (https=)
JP (1) JP2024513227A (https=)
KR (1) KR20230175222A (https=)
AU (1) AU2022255486A1 (https=)
BR (1) BR112023019435A2 (https=)
CA (1) CA3214042A1 (https=)
CO (1) CO2023014204A2 (https=)
IL (1) IL307258A (https=)
MX (1) MX2023011464A (https=)
PH (1) PH12023552774A1 (https=)
WO (1) WO2022216680A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
US20240158394A1 (en) * 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors
IL322520A (en) * 2023-02-24 2025-10-01 Japan Tobacco Inc Modified pyrazolopyrimidine compounds and their medical use
JP7729000B2 (ja) * 2023-02-24 2025-08-25 日本たばこ産業株式会社 ６－アルコキシピラゾロピリミジン化合物及びその医薬用途
CN121368589A (zh) * 2023-03-17 2026-01-20 万特斯治疗美国公司 用于抑制nlrp3的脲衍生物及其用途
WO2025067411A1 (zh) * 2023-09-28 2025-04-03 北京普祺医药科技股份有限公司 一种nek7抑制剂、药物组合物及其用途
WO2025140570A1 (zh) * 2023-12-29 2025-07-03 北京普祺医药科技股份有限公司 一种nek7抑制剂、药物组合物及其用途
WO2026064385A1 (en) * 2024-09-18 2026-03-26 Ventus Therapeutics U.S., Inc. Oxadiazolone inhibitors of nlrp3 and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047384A2 (en) * 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2019192962A1 (en) * 2018-04-05 2019-10-10 Merck Patent Gmbh Heteroaryl compounds as type ii irak inhibitors and uses hereof
CN111646995A (zh) * 2019-03-04 2020-09-11 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
WO2021041975A1 (en) * 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds
WO2021057877A1 (zh) * 2019-09-26 2021-04-01 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2006066174A1 (en) 2004-12-17 2006-06-22 Eli Lilly And Company Thiazolopyridinone derivates as mch receptor antagonists
KR20090064602A (ko) 2006-10-16 2009-06-19 노파르티스 아게 단백질 키나제 억제제로서 유용한 페닐아세트아미드
EP2170871A2 (en) 2007-06-26 2010-04-07 GlaxoSmithKline LLC Processes for preparing benzimidazole thiophenes
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
ES2658395T3 (es) 2012-04-04 2018-03-09 Rigel Pharmaceuticals, Inc. Inhibidores de proteína cinasa C y usos de los mismos
CN103420977B (zh) 2012-05-16 2016-06-22 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
BR112014030284B1 (pt) 2012-07-18 2021-11-30 Sunshine Lake Pharma Co., Ltd Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
ES2755772T3 (es) 2012-11-07 2020-04-23 Nerviano Medical Sciences Srl Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas
EP2997030B1 (en) 2013-05-14 2017-08-09 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
EA029412B1 (ru) 2013-06-28 2018-03-30 Бейджин, Лтд. Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf
WO2015117147A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
JP2017525727A (ja) 2014-08-26 2017-09-07 アスター バイオテック リミテッド ライアビリティ カンパニー プロテインキナーゼ阻害剤
CN105837575B (zh) 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
EA038421B1 (ru) 2015-12-30 2021-08-26 ВиПиЭс-3, ИНК. Соединения, ингибирующие металлоферменты
CN107513068A (zh) 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
JP6570776B2 (ja) 2016-06-20 2019-09-04 テグ−キョンプク メディカル イノベーション ファウンデーション 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物
JP6867417B2 (ja) 2016-06-21 2021-04-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのｎ−（置換フェニル）−スルホンアミド誘導体
EP3296297A1 (en) 2016-09-15 2018-03-21 Centre National De La Recherche Scientifique Benzimidazol derivatives for treating filovirus infection
EP3548476A4 (en) 2016-12-02 2020-05-20 Quentis Therapeutics, Inc. SMALL MOLECULAR IRE1 INHIBITORS
AU2018272986A1 (en) 2017-05-26 2019-12-12 Ichnos Sciences SA Novel inhibitors of MAP4K1
WO2018222917A1 (en) 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
WO2019196812A1 (zh) 2018-04-09 2019-10-17 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
US20210139484A1 (en) 2018-04-11 2021-05-13 Gossamer Bio Services, Inc. Dihydroisoquinoline-2(1h)-carboxamide and related compounds and their use in treating medical conditions
CN112243439A (zh) 2018-06-13 2021-01-19 百济神州有限公司 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途
WO2020135507A1 (zh) 2018-12-26 2020-07-02 杭州百新生物医药科技有限公司 一种多取代苯氨基嘧啶衍生物及其制备方法和用途
WO2020206583A1 (en) 2019-04-08 2020-10-15 Qilu Regor Therapeutics Inc. Kinase inhibitors and uses thereof
US20220389009A1 (en) 2019-10-01 2022-12-08 Goldfinch Bio, Inc. Substituted 1,6-naphthyridine inhibitors of cdk5
US12565481B2 (en) 2020-02-20 2026-03-03 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory 6,7-dimethoxy-3-(pyridin-2-yl)quinoline compounds for inhibiting RET
WO2021226547A2 (en) 2020-05-08 2021-11-11 Halia Therapeutics, Inc. Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
CN113717156B (zh) 2020-05-25 2023-05-09 南京红云生物科技有限公司 Egfr抑制剂、其制备方法及用途
GB202010464D0 (en) 2020-07-08 2020-08-19 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047384A2 (en) * 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2019192962A1 (en) * 2018-04-05 2019-10-10 Merck Patent Gmbh Heteroaryl compounds as type ii irak inhibitors and uses hereof
CN111646995A (zh) * 2019-03-04 2020-09-11 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
WO2021041975A1 (en) * 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds
WO2021057877A1 (zh) * 2019-09-26 2021-04-01 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途

Also Published As

Publication number Publication date
AU2022255486A1 (en) 2023-10-19
KR20230175222A (ko) 2023-12-29
IL307258A (en) 2023-11-01
BR112023019435A2 (pt) 2023-10-24
CO2023014204A2 (es) 2023-11-10
EP4320127A1 (en) 2024-02-14
CA3214042A1 (en) 2022-10-13
WO2022216680A1 (en) 2022-10-13
US20240317758A1 (en) 2024-09-26
MX2023011464A (es) 2023-10-19
PH12023552774A1 (en) 2024-04-15

Similar Documents

Publication Publication Date Title
JP2024513227A (ja) Ｎｅｋ７阻害剤
CN115843272B (zh) Nek7激酶的抑制剂
US10590079B2 (en) Cyano-substituted indoles as LSD1 inhibitors
CN106413716B (zh) 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤
JP7635237B2 (ja) ４－［［（７－アミノピラゾロ［１，５－ａ］ピリミジン－５－イル）アミノ］メチル］ピペリジン－３－オール化合物及びそれらの治療的使用
TWI908811B (zh) Nek7激酶抑制劑
CN108463222A (zh) 用于治疗疾病的杂环化合物
WO2022159835A1 (en) Nek7 inhibitors
WO2022212326A1 (en) Nek7 inhibitors
CN117597346A (zh) Nek7抑制剂
WO2024059200A1 (en) Nek7 inhibitors
EP4598907A1 (en) Phenyl oxy amide kinase inhibitors
US20250177382A1 (en) Nek7 inhibitors
RU2860767C2 (ru) Ингибиторы nek7
US20250388571A1 (en) Amp-activated protein kinase modulator compounds and uses thereof
HK40113746A (zh) 双环化合物用於治疗疾病的用途
HK40085586B (zh) 哒嗪基噻唑甲酰胺类化合物
HK40084227B (zh) 哒嗪基噻唑甲醯胺类化合物
HK40059656B (zh) 哒嗪基噻唑甲酰胺类化合物
HK1260375B (zh) 用於治疗疾病的杂环化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251223

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260319